BofA raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Buy rating on the shares. The firm is positive on the company’s decision to remain disciplined on the external growth front, but acknowledges the markets concern that it may fall behind as others shift to an offensive strategy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SBRA:
- Sabra Health Care REIT Reports Strong Q3 2024 Results
- Sabra Healthcare REIT Reports Strong Q3 2024 Performance
- Sabra Health Care narrows FY24 AFFO view to $1.41-$1.42 from $1.39-$1.42
- Sabra Health Care reports Q3 AFFO 37c, consensus 36c
- SBRA Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
